Use of midazolam in combination with medetomidine for premedication in healthy dogs by Le Chevallier, Delphine et al.
                          Le Chevallier, D., Slingsby, L., & Murrell, J. (2019). Use of midazolam in
combination with medetomidine for premedication in healthy dogs.
Veterinary Anaesthesia and Analgesia, 46(1), 74-78.
https://doi.org/10.1016/j.vaa.2018.08.001
Peer reviewed version
Link to published version (if available):
10.1016/j.vaa.2018.08.001
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://www.sciencedirect.com/science/article/pii/S1467298718302095?via%3Dihub. Please refer
to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
  
SHORT COMMUNICATION 
The use of midazolam in combination with medetomidine for premedication in 
healthy dogs 
 
Abstract  
Objective To assess the sedative effects, propofol sparing properties and impact on quality 
of induction and intubation of intravenous (IV) medetomidine and midazolam 
administered consecutively at different doses compared to medetomidine alone in healthy 
dogs for premedication.  
Study design Prospective, randomized, blinded, clinical study.  
Animals A total of 40 adult healthy client owned dogs, weighing 18 ± 7 kg (mean ± 
standard deviation). 
Methods Dogs were assigned to four groups: medetomidine 15 µg kg-1 (positive control 
group), medetomidine 10 µg kg-1& midazolam 0.2 mg kg-1, medetomidine 5 µg kg-1& 
midazolam 0.3 mg kg-1 and medetomidine 5 µg kg-1& midazolam 0.2 µg kg-1. The same 
clinician assessed sedation after administration at T2.5 minutes and T5 minutes using a 
composite simple descriptive sedation scale (CSDS) between 0 and 15 (0= no 
sedation;15=profound sedation). The dose of propofol for induction, quality of induction, 
ease of intubation and any adverse events were recorded.  
Results There was no significant difference in sedation scores between treatment groups at 
T2.5 minutes or T5 minutes (p=0.82 and p=0.63 respectively).  Administration of 
midazolam in combination with medetomidine resulted in 71% of dogs displaying 
paradoxical behaviours (p<0.0001) such as agitation, excitation, restlessness, aggression 
and vocalization which was different from pre-sedation.   Propofol requirement was not 
  
different between groups. Induction and tracheal intubation quality was smooth in all 
groups.  
Conclusion In healthy dogs, at the doses studied, the combination of medetomidine-
midazolam administered IV for premedication provided moderate sedation but was 
associated with a high incidence of paradoxical behaviours. This drug combination IV is 
not recommended for premedication in healthy dogs. 
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 Introduction  
In veterinary medicine, the number of dogs and cats premedicated  before general 
anaesthesia (GA) is reported to be rising to 100% (Brodbelt 2006) .  It has an important 
impact on the GA and decreases odd-ratios of anaesthetic deaths and complications 
(Brodbelt 2006). Furthermore, induction is smoother, faster and less induction agent is 
needed, minimizing side effects (Murrell 2016).  
Medetomidine combinations, although not as widely used as acepromazine 
combinations, are the second most common premedication agents in the UK (Brodbelt 
2006).  Medetomidine provides reliable and profound sedation with a significant drug 
sparing effect on anaesthetic induction and maintenance agents (Murrell 2016). Midazolam 
is a commonly used benzodiazepine agent for sedation and premedication in human 
medicine; providing propofol sparing effects and improving intubation quality (National 
Institute for Health and Care Excellence 2014). Alone, in healthy dogs it provides minimal 
sedation (Court & Greenblatt 1992). The combination has been described in a few 
experimental studies in dogs that suggest improved sedation and a decrease in propofol 
requirements compared to medetomidine alone (Hayashi et al. 1994; Canfrán et al. 2016).  
The aim of this study was to investigate the sedative effects, propofol sparing 
potential and effect on induction and intubation quality of the combination medetomidine-
midazolam compared to medetomidine alone administered IV as premedication prior to 
GA in healthy dogs.  
 
Materials and methods 
 
Animals  
  
The study protocol was approved by the University Animal Ethical Review Committee 
(VIN/15/033) and informed owner consent was obtained for all dogs enrolled in the study. 
The study was also conducted under an Animal Test Certificate (42273/003) and complied 
with Good Clinical Practice standards. A total of 40 client-owned dogs presenting for 
elective neutering at a practice were recruited. All animals were healthy based on full 
clinical examination, were classified as American Society of Anesthesiologists (ASA) I or 
II, had no or mild pain at presentation and weighed between 10 and 40 kg. Exclusion 
criteria were dogs not healthy on clinical exam, previous sedation or GA in the last 48 
hours or IV catheter placement was not possible whilst conscious. One investigator 
collected all the data, received training for the sedation scoring system and was unaware of 
treatment allocation.  
 
Study design and treatments  
Administration of the premedication combinations was pseudorandomised depending on 
body weight [10-25 kg (SSMALL) and 26-40 kg (SLARGE)] into four groups: 
medetomidine 15 µg kg-1 [Med15 (positive control)], medetomidine 10 µg kg-1 & 
midazolam 0.2 mg kg-1 (Med10mid0.2), medetomidine 5 µg kg-1 & midazolam 0.3 mg kg-1 
(Med5mid0.3) and medetomidine 5 µg kg-1 & midazolam 0.2 mg kg-1 (Med5mid0.2). The 
treatment administrator was a registered veterinary nurse who was not involved in data 
collection.  
All drugs, medetomidine (1 mg mL-1, Sedastart; Animal Care Limited) and 
midazolam (5 mg mL-1, Dormazelam, Regivet BV) were administered intravenously (IV) 
over 60 seconds via a preplaced intravenous catheter in separate syringes and flushed with 
1 mL of heparin saline (5 IU mL-1) in between. The medetomidine was always 
administered first followed immediately by midazolam.
  5 
Experimental protocol  1 
Once admitted, baseline vital parameters and sedation score were recorded. An intravenous 2 
catheter was placed. The investigator was unaware of the treatment allocation and did not 3 
observe the preparation and administration of the test drugs.  The investigator returned to the 4 
induction area to observe the dog immediately after the test drug administration to allow 5 
scoring of sedation before induction of anaesthesia using a composite simple descriptive scale 6 
(CSDS) ranging from 0 (no sedation) to (15) profound sedation (Appendix A). The time of 7 
test drug administration was Time 0 (T=0); sedation were scored again at T2.5 minutes and 8 
T5 minutes. Any adverse events during the premedication period were recorded.   9 
The investigator induced anaesthesia five minutes after the test drug administration. 10 
Propofol was administered slowly IV to effect in 0.5 mg kg-1 aliquots and after each dose, depth 11 
of anaesthesia was assessed by checking for presence or absence of a palpebral reflex and 12 
assessment of jaw tone. Tracheal intubation was attempted when there was loss of a palpebral 13 
reflex and the jaw tone was relaxed. The dose of propofol required to allow successful 14 
intubation was recorded. Quality of induction and quality of intubation was scored using a 15 
simple descriptive scale ranging from 0  to 3  (Appendix B).  16 
Immediately after induction of anaesthesia and tracheal intubation, the endotracheal tube 17 
was connected to the circle breathing system and the cuff was inflated to effect until there was 18 
no audible leak when the reservoir bag was squeezed.  The anaesthetic machine delivered 19 
isoflurane vaporised at 2% in 100% oxygen and methadone 0.2 mg kg-1 was administered IV. 20 
The rest of the GA was monitored and performed as normal.  21 
 22 
Statistics 23 
A power calculation to determine sample size was based on the study by Raszplewicz et al. 24 
(2013) using the same composite sedation scoring system. They indicated that 17 dogs per 25 
  6 
group were needed for a statistical power of 90% to detect a difference in sedation scores of 26 
25% with an alpha error of 0.05. Therefore, it was decided to recruit 20 dogs per group in the 27 
present investigation. Because of the important number of side effects observed, the study was 28 
terminated at 40 dogs instead of 80. 29 
 Data were assessed for normality and homogeneity of variance with the appropriate 30 
statistical tools. Appropriate tests for parametric and non-parametric data were chosen and 31 
data were analysed using SPSS 18 (IBM, NY). One way ANOVA between groups was used 32 
to compare body weight, sedation score at T2.5 minutes and T5 minutes, and dose of 33 
induction agent.  The assumptions of 'normality of errors' and 'homogeneity of variance' were 34 
met  35 
Quality of induction and intubation were assessed using a Kruskal Wallis analysis of variance.  36 
A Chi-square test was used to compare the number of dogs per treatment group, signs of 37 
paradoxical behaviour at premedication and side effects. When post-hoc testing was carried 38 
out, the p value at 0.05 was adjusted by Bonferroni correction p/n . 39 
 40 
Results 41 
Only 40 dogs were recruited for the study; because of ethical reasons the study was 42 
terminated early. This caused the treatment groups to be unbalanced with 12 dogs in groups 43 
med15, 9 in group med10mid0.2, 10 in group med5mid0.3 and 9 in group med5mid0.2. There 44 
were no significant differences in age (p= 0.95) or body weight (p=0.74) between the 45 
treatment groups.  46 
The sedation score increased over time after treatment administration in all the groups 47 
(p<0.005). There was not an effect of treatment group on sedation scores over time (p=0.84). 48 
When compared at individual time points at T2.5 and T5, there was not a difference between 49 
treatment groups (p=0.82) (p=0.63). Similarly, there were no differences in the dose of 50 
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propofol (mg kg-1) required for induction(p=0.31) (Table 1), the quality of induction (p=0.3) 51 
or the quality of tracheal intubation between treatment groups (p=0.8).  52 
After administration of the test drug(s), some dogs showed signs of agitation, 53 
excitation, significant hypersensitivity to noise, restlessness, abnormal change in behaviour, 54 
aggression and vocalization defined as paradoxical behaviour, which was significantly 55 
different from the pre-sedation state. Dogs premedicated with midazolam (groups 56 
med10mid0.2, med5mid0.3, med5mid0.2) were significantly more likely to have paradoxical 57 
behaviours, 71 % of cases administered midazolam had paradoxical behaviours (p<0.0001) 58 
(Table 1).  59 
 60 
Discussion 61 
This study found that consecutive administration of medetomidine and midazolam to healthy 62 
dogs provided moderate sedation with severe paradoxical behaviours.  63 
The similar sedation scores between treatments may be associated with the profound 64 
effect of medetomidine so that midazolam may not have a significant additive effect when 65 
combined with medetomidine (Canfràn et al. (2016). While midazolam in human medicine 66 
produces sedation, given alone to healthy dogs, it is associated with paradoxical behaviours 67 
(Covey-Crump & Murison 2008; Sanchez et al. 2013). Sanchez et al. (2013), in sedated dogs, 68 
found that the administration of midazolam 0.2 mg kg-1 IV resulted in either no change in 69 
degree of sedation or mild to moderate excitement (Sanchez et al. 2013). Covey-Crump and 70 
Murison (2008) also suggested that dogs already sedated became ‘less sedated’ and excited 71 
after administration of midazolam 0.2 mg kg-1 IV as a co-induction agent (Covey-Crump & 72 
Murison 2008).  73 
Our findings strongly support previous reports of paradoxical behaviours associated 74 
with midazolam administration to healthy dogs. This is characterised by restlessness, 75 
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vocalisation and hyper-responsiveness to sound and aggression. In this study 20 out of 28 76 
dogs that received midazolam, displayed excitatory signs after IV administration.  77 
Comparatively to other drugs, α2-agonists are the most potent sedatives in veterinary 78 
medicine. At normal clinical doses medetomidine is an effective and potent sedative. 79 
Consequently, the frequency of excitement associated with the combination of midazolam and 80 
medetomidine was unexpected in the study. The pharmacokinetics of medetomidine and 81 
midazolam may be responsible. While medetomidine IV at 40 µg kg-1, reaches peak plasma 82 
concentrations between 10-15 minutes, midazolam IV takes less than 3 minutes (Court & 83 
Greenblatt 1992; Kuusela et al. 2000). 84 
Quality of tracheal intubation was no different between treatment groups. It was 85 
hypothesised that dogs premedicated with midazolam and medetomidine would have better 86 
quality intubation compared with medetomidine alone. Previous studies have recorded a 87 
smoother intubation after administration of midazolam, believed to be associated with its 88 
effects on upper airway reflexes (Covey-Crump & Murison 2008). Within the veterinary 89 
literature, medetomidine is described as providing smooth conditions for intubation, although 90 
there are no previous reports assessing quality with a numerical descriptive scale, similar to 91 
our study. In human medicine, the addition of dexmedetomidine to midazolam showed more 92 
smooth intubation compared to midazolam alone (Bergese et al. 2010). 93 
The quality of induction was generally smooth and was similar between treatments. 94 
Medetomidine as premedication provides good quality induction without excitement (Murrell 95 
2016). On the other hand, midazolam, given prior to propofol in mildly sedated dogs, has 96 
been reported to be associated with a lower quality induction (Covey-Crump & Murison 97 
2008). Our results suggest that the combination of medetomidine-midazolam provides smooth 98 
induction. This is most probably associated with the prevailing effect of medetomidine. 99 
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This clinical study had several limitations. First, the number of dogs recruited was not 100 
equal to the number initially calculated in the power analysis. Based on previous reports, to 101 
detect a 25% difference in sedation scores, 17 dogs per treatment group were needed 102 
(Raszplewicz et al. 2013). We recruited only 40 dogs, so the study is underpowered for the 103 
primary outcome. Nevertheless, from the results of the sedation score at T5, with a p value of 104 
0.6, it is unlikely that a true effect would have been detected with more dogs. The high 105 
incidence of paradoxical behaviours associated with midazolam administration was an ethical 106 
reason to stop the study. However it also may have biased the assessment outcome because, 107 
although the assessor was blinded to the treatment allocation, the typical behaviours were 108 
obvious. Any analytical techniques, to correct these limitation and solutions, such as 109 
involving a second assessor, would have been impractical and would have inevitably 110 
increased variability in the outcome measures.  111 
 112 
Conclusions 113 
In healthy dogs, medetomidine and midazolam given consecutively IV does not provide 114 
reliable sedation and is associated with severe behavioural changes. Ease of intubation and 115 
induction were not improved and the results do not suggest that it reduced propofol 116 
requirements.  117 
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